A Randomized Phase III Trial of Adjuvant Therapy comparing Doxorubicin plus Cyclophosphamide followed by Weekly Paclitaxel with or without Carboplatin for node positive or high risk node negative triple negative invasive breast cancer
Female: PS 0-1; Invasive Breast Cancer; pT1-3; pN0, pN1; pN2a, pN2b; pN3a or pN3b; If pN0 must be one of the following :
pTx and ER- and PgR negpT2 and ER+ and either grade 3 or Oncotype Dx > 25
Her 2 status evaluated prior to randomization as HER2 low IHC staining of 1+ (ISH testing is not required) or 2+ FISH or CISH must also be performed and must indicate no more than 84 days post op
Stivarga Management Amelioration Resorting Technology: Does Physician Education Infuence side effect management and does it increase time on treatment in the absence of progression? A phase 4 open label trial with regrafenib in metastatic colorectal cancer
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials
A Phase III, Open Label, randomized study of MPDL3280A (Anti PDL1 Antibody) compared with Cisplatin or Carboplatin + pemetrexed for PD-L1 selected, chemotherapy naïve patients with stage IV Non Small Cell Lung Cancer
A Phase III, open label, randomized study of MPDL3280A (anti-PDL1 antibody) compared with gemcitabine +Cisplatin or Carboplatin for PD-L1-selected, chemotherapy-naïve patients with stage IV squamous non small cell lung cancer
Diagnosis within 180 days: moderate to high risk:
Gleason score 7-10 + T1c-T2b+PSA<50Gleason Score 6+T2c-T4 or >50% positive biopsies+PSA<50Gleason Score + T1c-T2b +PSA >20
No prior surgery, radiation, hormone ablation
Several web-based resources have been developed to facilitate patient access to and information about clinical trials performed in hospitals and clinics around the country. Searchable databases of national clinical trials are also available through the National Cancer Institute and the Southeast Cancer Control Consortium.
The Wellmont Cancer Institute offers clinical trial opportunities at our Kingsport, Bristol and Southwest Virginia cancer centers. If you're looking for more information or have questions about this program, please contact us.
You clicked on a link that will cause you to leave myWellmont.
For security purposes you will be signed out.